• About Us
  • Privacy
  • Contact Us

Contact Lens Update

Clinical Insights Based in Current Research

Search Our Site

  • Home
  • Browse Past Issues
  • Resource Library
  • Back to Basics
  • Useful Links
  • About Us
  • Contact Us

Conference Highlights

A Phase I/II clinical study evaluating the safety and effectiveness of a topical lipoic acid choline ester eye drop on presbyopia

December 13th, 2017
Michael KorenfeldMichael S. Korenfeld is an ophthalmologist and the owner of a private practice. He is also an Assistant Clinical Professor at the Washington University School of Medicine.    

Download the poster (.pdf), which was originally shared at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, 2017.


A Phase I/II clinical study evaluating the safety and effectiveness of a topical lipoic acid choline ester eye drop on presbyopia

Michael S. Korenfeld,1,2 David G. Evan,3 Steven H. Rauchman,4 Kenneth N. Sall,5 Jerry M. Stein,6 Stella M. Robertson,7 Travis Whitfill,8 Judy Gordon,9 William Burns,10 Adrian Glasser11

1 Ophthalmology and Visual Sciences, Washington University, St. Louis, Missouri, United States
 2 Ophthalmology and Visual Sciences, Comprehensive Eye Care, Ltd, Washington, Missouri, United States
3 Total Eye Care, PA, Memphis, Tennessee, United States
4 North Valley Eye Medical Group, Mission Hills, California, United States
5 Sall Research Medical Center, Artesia, California, United States
6 Summer Creek Consulting, LLC, Fort Worth, Texas, United States
7 Arrochar Consulting, LLC, Fort Worth, Texas, United States
8 Bios Partners, Fort Worth, Texas, United States
9 ClinReg Consulting Services, Inc, Laguna Beach, California, United States
10 Encore Vision, Inc, Fort Worth, Texas, United States
11 Adrian Glasser Consulting Services, Tampa, Florida, United States

Lipoic acid (LA) is an antioxidant shown to chemically reduce disulfide bonds and allow greater cytosol displacement in crystalline lenses preclinically (Garner and Garner, 2016). This pharmacologic activity has the potential to improve distance corrected near vision in presbyopes. An LA choline ester (EV06 Ophthalmic Solution, 1.5%) was formulated to deliver a clinically effective concentration of LA to the lens when dosed topically.

Purpose: This first-in-humans study was a preliminary assessment of EV06 safety and efficacy for the treatment of presbyopia.

Methods: 75 subjects were recruited at 4 sites in a randomized, double-masked, placebo controlled study. Subjects were generally healthy males or females, 45-55 years old meeting eligibility criteria including Distance Corrected Near Visual Acuity (DCNVA) worse than 20/40 in each eye and manifest refraction spherical equivalent between or equal to +4.0D to -4.0D. DCNVA was assessed using EDTRS charts (M&S CTS System). Following informed consent, subjects were randomized to EV06 (n = 50) or placebo (n = 25). On Days 1-7, all subjects dosed unilaterally (bid) to ensure safety prior to Days 8–91 when dosing was bilateral (bid).

Results: Acceptable safety was indicated. 72 of 75 subjects completed the study (EV06 n = 49; placebo n = 23) and no subjects discontinued for drug related ocular adverse events. Improvement in DCNVA was observed in the EV06 group compared to the placebo group, with the onset of statistically significant differences in DCNVA OU beginning on Day 15 (placebo vs EV06, mean ± SEM; 0.375 ± 0.028 vs 0.290 ± 0.021 LogMAR; p = 0.017) and continuing throughout the 3-month study (Day 91: 0.313 ± 0.030 vs 0.206 ± 0.021 LogMAR; p = 0.005). The percentage of subjects with DCNVA OU of 20/32 or better at baseline was 8.0% in both the EV06 and placebo groups (p = 1.00) compared to 60.0% and 24.0% on Day 91 (p = 0.004), respectively.

Conclusions: These results support further development of this treatment.

Related Articles

  • December 13, 2017

    Where are we heading with contact lenses for presbyopes?

  • December 13, 2017

    Pupil diameter, working distance and illumination during habitual tasks. Implications for simultaneous vision contact lenses for presbyopia

  • December 13, 2017

    A Phase I/II clinical study evaluating the safety and effectiveness of a topical lipoic acid choline ester eye drop on presbyopia

  • December 13, 2017

    Patient handout: Presbyopia

Issues

  • Multifocal Contact Lenses
  • Artificial Tears: An Update
  • Myopia: New Evidence and Best Practices
  • Neuropathic Pain
  • Specialty Rigid Lenses
  • Contact lens compliance
  • Pandemic update
  • Digital Devices and Dry Eye: A Growing Issue
  • The long and short of axial length
  • Using BCLA CLEAR with your patients
  • Helping your patients through allergy season
  • Getting the measure of meibomian glands
  • 2020: An extraordinary year
  • Scleral lens update
  • A dose of myopia
  • New news since TFOS DEWS II
  • COVID-19 Special Edition
  • Material considerations
  • Putting dry eye theory into practice
  • Getting started with Ortho-K
  • Infiltrates – an update
  • Staining
  • Myopia matters: Summarising the IMI reports
  • Lids and contact lenses
  • Myths
  • Revisiting patient compliance
  • Contact Lenses & Kids
  • Interprofessional Collaboration
  • Digital eye strain
  • New Dry Eye Technology
  • Update on Presbyopia
  • Taking stock of dry eye disease: DEWS II
  • Scleral Lenses
  • Pain and Sensation
  • Lab measurements in clinical practice
  • Control of pediatric myopia
  • Nutrition
  • Rethinking contact lens deposits
  • Extended wear
  • Daily Disposables
  • Eyelash Mites (Demodex)
  • Outsmarting bacteria with new technology
  • Youth and contact lenses
  • Sports Vision
  • Ocular effects of UV radiation from the sun
  • Eyelid Conditions
  • Makeup: Impact on ocular health
  • Myopia Control – Update 2014
  • The Growing Prevalence of Myopia
  • Cosmetic contact lenses
  • Contact lens discomfort – The essentials
  • Technology and contact lens research
  • It's A Question of Comfort
  • Contact lens materials
  • Let's talk about SICS
  • Conjunctival Controversies
  • Kids & Contact Lenses
  • One-day silicone hydrogel lenses
  • Solutions
  • Spotlight on Scleral lenses
  • Drug delivery via contact lenses
  • Ocular allergies
  • Reducing lens case contamination
  • Dry eye and meibomium gland dysfunction
  • Myopia Control
  • Presbyopia
  • Compliance and non-compliance
  • Lens care
  • Celebrating 50 years of contact lenses

Looking for another article?

Alcon coopervision Johnson&Johnson Vision Care

Newsletter Sign-Up

Sign-up for and start receiving our newsletter.

Site Map

  • Home
  • Browse Past Issues
    • Editorial
    • Feature Article
    • Clinical Insight
    • Conference Highlights
  • Resource Library
  • Back to Basics
  • Useful Links
  • About Us
  • Contact Us
© 2023 Contact Lens Update